Spots Global Cancer Trial Database for plasmacytoma
Every month we try and update this database with for plasmacytoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | NCT02184533 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... Multiple Myelom... Plasmacytoma | sodium selenite radiation thera... laboratory biom... pharmacological... questionnaire a... | 18 Years - | Stanford University | |
| A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | NCT00821249 | Multiple Myelom... Plasma Cell Leu... | ARRY-520, KSP(E... Filgrastim, gra... Dexamethasone, ... | 18 Years - | Pfizer | |
| A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | NCT04174196 | Plasmacytoma Plasmacytoma of... Multiple Myelom... | CC-486 Lenalidomide Radiation Thera... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | NCT02184533 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... Multiple Myelom... Plasmacytoma | sodium selenite radiation thera... laboratory biom... pharmacological... questionnaire a... | 18 Years - | Stanford University | |
| The Indiana Myeloma Registry | NCT03616483 | Plasma Cell Dys... | This is a non-i... | 18 Years - | Indiana University | |
| Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | NCT02921893 | Plasmacytoma POEMS Syndrome | Dexamethasone Ixazomib Citrat... Lenalidomide Questionnaire A... | 18 Years - | Mayo Clinic | |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | NCT03031730 | Plasmacytoma Recurrent Multi... Refractory Mult... | Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin | 18 Years - | National Cancer Institute (NCI) | |
| Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma | NCT03312868 | Plasmacytoma | SBRT | 18 Years - 85 Years | Instituto do Cancer do Estado de São Paulo | |
| The Indiana Myeloma Registry | NCT03616483 | Plasma Cell Dys... | This is a non-i... | 18 Years - | Indiana University | |
| Phase I/II Study of hLL1 in Multiple Myeloma | NCT00421525 | Multiple Myelom... Myeloma, Plasma... PLASMACYTOMA | milatuzumab | 18 Years - | Gilead Sciences | |
| UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma | NCT00569868 | MULTIPLE MYELOM... | Velcade | 18 Years - | University of Arkansas | |
| A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | NCT00821249 | Multiple Myelom... Plasma Cell Leu... | ARRY-520, KSP(E... Filgrastim, gra... Dexamethasone, ... | 18 Years - | Pfizer | |
| S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | NCT00109889 | Multiple Myelom... Plasmacytoma | magnetic resona... positron emissi... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone | NCT00911105 | Multiple Myelom... | 18 Years - | iOMEDICO AG | ||
| Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy | NCT02303353 | Carcinoma | 18 Years - | SPGO Research Mannheim GmbH | ||
| A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | NCT01248923 | Multiple Myelom... | ARRY-520, KSP(E... Bortezomib, pro... Dexamethasone, ... Filgrastim, gra... ARRY-520, KSP(E... Bortezomib, pro... Filgrastim, gra... | 18 Years - | Array BioPharma | |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | NCT02506959 | Plasma Cell Leu... Plasmacytoma Recurrent Plasm... Refractory Plas... | Autologous Hema... Busulfan Gemcitabine Hyd... Laboratory Biom... Melphalan Panobinostat Peripheral Bloo... Pharmacological... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | NCT00109889 | Multiple Myelom... Plasmacytoma | magnetic resona... positron emissi... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| An Open Protocol for the Compassionate Use of Thalidomide | NCT00081757 | Multiple Myelom... | Thalidomide | 18 Years - | University of Arkansas | |
| Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma | NCT02544308 | Plasmacytoma | Lenalidomide Dexamethasone No further trea... | 18 Years - | University College, London | |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | NCT01248923 | Multiple Myelom... | ARRY-520, KSP(E... Bortezomib, pro... Dexamethasone, ... Filgrastim, gra... ARRY-520, KSP(E... Bortezomib, pro... Filgrastim, gra... | 18 Years - | Array BioPharma | |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | NCT02506959 | Plasma Cell Leu... Plasmacytoma Recurrent Plasm... Refractory Plas... | Autologous Hema... Busulfan Gemcitabine Hyd... Laboratory Biom... Melphalan Panobinostat Peripheral Bloo... Pharmacological... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | NCT03031730 | Plasmacytoma Recurrent Multi... Refractory Mult... | Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin | 18 Years - | National Cancer Institute (NCI) | |
| An Open Protocol for the Compassionate Use of Thalidomide | NCT00081757 | Multiple Myelom... | Thalidomide | 18 Years - | University of Arkansas |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
